Fuji Pharma (4554) · InitiativeRestated
New Borrowings for Alvotech Share Acquisition and Working Capital
First written in FY2019-Q1. 1 of 2 entries say "Restated". Latest entry: FY2019-Q2.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Borrowing to Fund M&A and Growth InvestmentsA theme 78 companies write about · 3 as a headwind · 81 as a tailwind
5 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 78 companies compared. The sentences above are computed from all 78.Full recordFilings, disclosures and news, newest first
- FY2019-Q2RestatedAnnual report
「Although there was income of ¥7,000 million from long-term borrowings, financing activities provided income of ¥6,068 million, mainly due to dividend payments of ¥419 million, compared with an outflow of ¥1,332 million in the same period of the previous year.」
The new borrowings executed in connection with the acquisition of Alvotech HD shares and working capital are also confirmed in the financial statements as ¥7,000 million in proceeds from long-term borrowings during the current quarter. - FY2019-Q1First statedAnnual report
「Based on a resolution of the Board of Directors held on 15 November 2018, we executed the following new borrowings to finance the acquisition of shares in Alvotech Holdings and working capital.」
On 4 January 2019, we borrowed ¥4,000 million from Sumitomo Mitsui Banking Corporation and ¥3,000 million from Mizuho Bank to finance the acquisition of shares in Alvotech Holdings and working capital. The respective repayment dates are 29 December 2023 and 30 November 2023, and no assets have been pledged as collateral.